BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution

新聞報導於大約19小時前

撰寫摘要中...

您可能也對這些小見聞有興趣

Wall Street Has a Mixed Opinion on Enovix Corporation (ENVX) Ahead of FQ3 2025 Results

Rare earth stocks climb, Bloom Energy deal, Fastenal earnings

BofA Raises Franklin Resources (BEN) PT to $22, Keeps Underperform Rating

Cantor Fitzgerald Raises NVDA Price Target, Keeps Overweight Rating

SailPoint Identity Security Cloud Gains New Capabilities for Non-Employee and Machine Identities

HELOC rates today, October 13, 2025: Rates are steadily decreasing throughout the year

Warburg Pincus to buy Germany's PSI for over 700 million euros

'We Spend a Couple of Weeks Every Summer Out of the Country': Couple Runs 15 Properties and Calls It a 10-Hour-a-Month Job

Wells Fargo Lowers PT on Dana Incorporated (DAN), Keeps an Overweight Rating

China's state iron ore buyer offers BHP cargoes for sale amid ban fears

返回所有小見聞